Arkolith/Insider Trading/AMAM/Form 4

Rupalla Katrin

DirectorAmbrx Biopharma Inc. (AMAM) · full profile →Form 4 · filed Jan 31, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
0 non-derivative · 4 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 27, 2023Grant(A)105K——105K
Jan 27, 2023Disposed to issuer(D)105K——0
Jan 27, 2023Grant(A)200K——200K
Jan 27, 2023Disposed to issuer(D)200K——0

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-005792) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML